Physician profile
Muhammad Munir
NPI 1295838407
$1,458.94
in general payments reported to CMS, 2019-2025
8 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.27 · 2021: $134 · 2022: $56.35 · 2023: $484 · 2024: $506 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989 · Travel and Lodging: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.17 |
| Travel and Lodging | $246.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $686.57 | 2022-2025 | Qelbree, Qelbree |
| Abbott Laboratories | $470.89 | 2021-2024 | Aveir, Viewmate |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.51 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $83.44 | 2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $32.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.00 | 2024 | Entyvio |
| Harmony Biosciences LLC | $23.82 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.44 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.